Avelumab Program Rollover Study

This study is for adults aged 18 and over who have solid tumours and are already enrolled in, and receiving treatment with avelumab in, another specific avelumab clinical study sponsored by EMD Serono Research & Development Institute, Inc. / Merck KGaA, Darmstadt, Germany, or Merck Serono Co., Ltd (Japan). You can also join if you've finished treatment in the previous study but are still being followed up to see how you're doing in the long term.

To be eligible, if you are still receiving treatment and there's a chance of pregnancy, you (and your male partner, if applicable) must agree to use highly effective contraception. This means birth control methods that have a very low chance of failing (less than 1% per year).

However, you cannot take part if you are pregnant or breastfeeding. Also, if you know you are highly sensitive or allergic to any ingredients in avelumab, this study would not be suitable for you. You also can't join if you were in the comparison group of the previous avelumab study (meaning you didn't receive avelumab), or if you had to leave the previous study for any reason. Your study doctor will make the final decision based on your overall health.

If you join this study, your participation will mainly involve continuing your avelumab treatment as you have been doing in your original study. This means you will keep receiving the medicine according to the same plan. The study team will closely monitor your health, checking for any side effects and making sure the treatment continues to be suitable and safe for you. This will likely involve regular check-ups and assessments, similar to what you've experienced before, to track your progress and well-being. The total length of your participation will depend on your individual treatment plan and how long you need to continue receiving avelumab.